Figures & data
Figure 1 Protocol for the experiment. (A) Acute and (B) chronic ranitidine administration in dyskinetic rats.
Figure 2 Effects of acute ranitidine administration on axial/limb/orolingual AIMS and rotations in levodopa (25 mg/kg) + benserazide (12.5 mg/kg)-primed, hemiparkinsonian rats (n=7).
Figure 3 Effects of chronic ranitidine administration on AIMS and rotations in seven hemiparkinsonian rats primed with levodopa (25 mg/kg) + benserazide (12.5 mg/kg).
Abbreviation: AIMS, abnormal involuntary movements.
Figure 4 Effects of ranitidine on motor performance in the forepaw adjusting steps test in seven hemiparkinsonian rats primed with levodopa (25 mg/kg) + benserazide (12.5 mg/kg). *P<0.05, versus levodopa + vehicle group; **P<0.01 versus levodopa + vehicle group. The data were analyzed by one-way analysis of variance, followed by the Newman-Keuls post hoc test.
Figure 5 Treatment with ranitidine prevented an increase in Arc and Penk. Arc and Penk levels were increased in PD rats. Repeated levodopa treatment induced further increased expression of Arc and Penk levels. Conversely, ranitidine prevented the increase of Arc and Penk (seven rats per group). (A) *P<0.05 versus sham group; #P<0.01 versus PD group; ##P<0.01 versus levodopa group. (B) *P<0.05 versus sham group; **P<0.01 versus PD group; #P<0.05 versus levodopa group. The data were analyzed by one-way analysis of variance, followed by the Newman-Keuls post hoc test.
